TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer’s disease hippocampus

Clinical Epigenetics

Volumn 8, Issue 1, 2016, Pages

  Celarain, Naiara ^a   Sánchez Ruiz de Gordoa, Javier ^a,b,d   Zelaya, María Victoria ^b   Roldán, Miren ^a   Larumbe, Rosa ^a,b   Pulido, Laura ^a,b,d   Echavarri, Carmen ^a,c   Mendioroz, Maite ^a,b  

^a IdiSNA Navarra Institute for Health Research   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c Hospital Psicogeriátrico Josefina Arregui   (Spain)

^d Clinica San Miguel   (Spain)

Author keywords

5 Hydroxymethycytosine; Alzheimer s disease; DNA methylation; Epigenetics; Gene expression; TREM2

Indexed keywords

5 HYDROXYMETHYCYTOSINE; CYTOSINE DERIVATIVE; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HETEROZYGOSITY; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MOLECULAR CLONING; MORPHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FOLDING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION SITE; UPREGULATION; ADULT; AGED; ANALOGS AND DERIVATIVES; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CYTOSINE; DNA METHYLATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HIPPOCAMPUS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; UP-REGULATION;

EID: 84962172917     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-016-0202-9     Document Type: Article

References (51)

1. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109(4):1144–56. doi:10.1111/j.1471-4159.2009.06042.x.
2. Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina Bordignon P, et al. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem. 2009;110(1):284–94. doi:10.1111/j.1471-4159.2009.06130.x.
3. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201(4):647–57. doi:10.1084/jem.20041611.
4. Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Mol Neurodegener. 2013;8:19. doi:10.1186/1750-1326-8-19.
5. Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):449–53. doi:10.1001/jamaneurol.2013.6237.
6. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27. doi:10.1056/NEJMoa1211851.
7. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16. doi:10.1056/NEJMoa1211103.
8. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20. doi:10.1186/1750-1326-9-20.
9. Lue LF, Schmitz C, Walker DG. What happens to microglial TREM2 in Alzheimer’s disease: immunoregulatory turned into immunopathogenic? Neuroscience. 2014. doi:10.1016/j.neuroscience.2014.09.050.
10. Rohn TT. The triggering receptor expressed on myeloid cells 2: “TREM-ming” the inflammatory component associated with Alzheimer’s disease. Oxid Med Cell Longev. 2013;2013:860959. doi:10.1155/2013/860959.
11. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86. doi:10.1126/scitranslmed.3009093.
12. Abduljaleel Z, Al-Allaf FA, Khan W, Athar M, Shahzad N, Taher MM, et al. Evidence of trem2 variant associated with triple risk of Alzheimer’s disease. PLoS One. 2014;9(3):e92648. doi:10.1371/journal.pone.0092648.
13. Zhao Y, Hill JM, Bhattacharjee S, Percy ME, Pogue AI, Lukiw WJ. Aluminum-induced amyloidogenesis and impairment in the clearance of amyloid peptides from the central nervous system in Alzheimer’s disease. Front Neurol. 2014;5:167. doi:10.3389/fneur.2014.00167.
14. Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2014;39(13):2949–62. doi:10.1038/npp.2014.164.
15. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71. doi:10.1016/j.cell.2015.01.049.
16. Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):495–8. doi:10.1016/j.bcp.2013.11.021.
17. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56(13):1438–47. doi:10.1002/glia.20710.
18. Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, et al. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging. 2013;34(12):2699–714. doi:10.1016/j.neurobiolaging.2013.05.001.
19. Martiskainen H, Viswanathan J, Nykanen NP, Kurki M, Helisalmi S, Natunen T, et al. Transcriptomics and mechanistic elucidation of Alzheimer’s disease risk genes in the brain and in vitro models. Neurobiol Aging. 2014. doi:10.1016/j.neurobiolaging.2014.09.003.
20. Strobel S, Grunblatt E, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S et al. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARgamma. J Neural Transm. 2015. doi:10.1007/s00702-015-1369-5.
21. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG. TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol (Zurich, Switzerland). 2015;25(4):469–80. doi:10.1111/bpa.12190.
22. Zhao Y, Bhattacharjee S, Jones BM, Dua P, Alexandrov PN, Hill JM, et al. Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. Neuroreport. 2013;24(6):318–23. doi:10.1097/WNR.0b013e32835fb6b0.
23. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.
24. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell. 2012;151(7):1417–30.
25. Colquitt BM, Allen WE, Barnea G, Lomvardas S. Alteration of genic 5-hydroxymethylcytosine patterning in olfactory neurons correlates with changes in gene expression and cell identity. Proc Natl Acad Sci U S A. 2013;110(36):14682–7. doi:10.1073/pnas.1302759110.
26. Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X et al. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol. 2015. doi:10.1001/jamaneurol.2015.0979.
27. Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard AC, Rollin-Sillaire A, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer’s disease. J Alzheimers Dis. 2013;35(1):45–9. doi:10.3233/jad-122311.
28. Tang Y, Li T, Li J, Yang J, Liu H, Zhang XJ, et al. Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson’s disease. Cell Death Differ. 2014;21(3):369–80.
29. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39(4):457–66.
30. Villar-Menendez I, Blanch M, Tyebji S, Pereira-Veiga T, Albasanz JL, Martin M, et al. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington’s disease. Neuromolecular Med. 2013;15(2):295–309. doi:10.1007/s12017-013-8219-0.
31. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197–211. doi:10.1101/gr.132662.111.
32. Munzel M, Globisch D, Bruckl T, Wagner M, Welzmiller V, Michalakis S, et al. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angewandte Chemie. 2010;49(31):5375–7. doi:10.1002/anie.201002033.
33. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324(5929):929–30. doi:10.1126/science.1169786.
34. Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci. 2011;14(12):1607–16. doi:10.1038/nn.2959.
35. Chouliaras L, van den Hove DL, Kenis G, Keitel S, Hof PR, van Os J, et al. Age-related increase in levels of 5-hydroxymethylcytosine in mouse hippocampus is prevented by caloric restriction. Curr Alzheimer Res. 2012;9(5):536–44.
36. Chen H, Dzitoyeva S, Manev H. Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor Neurol Neurosci. 2012;30(3):237–45. doi:10.3233/RNN-2012-110223.
37. Coppieters N, Dieriks BV, Lill C, Faull RL, Curtis MA, Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer’s disease human brain. Neurobiol Aging. 2014;35(6):1334–44. doi:10.1016/j.neurobiolaging.2013.11.031.
38. Wu H, D’Alessio AC, Ito S, Wang Z, Cui K, Zhao K, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 2011;25(7):679–84. doi:10.1101/gad.2036011.
39. Irwin RE, Thakur A, O' Neill KM, Walsh CP. 5-Hydroxymethylation marks a class of neuronal gene regulated by intragenic methylcytosine levels. Genomics. 2014;104(5):383–92.
40. Bell JE, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Budka H, et al. Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol. 2008;115(5):497–507. doi:10.1007/s00401-008-0360-8.
41. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404. doi:10.1007/s00401-006-0127-z.
42. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. doi:10.1016/j.jalz.2011.03.005.
43. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
44. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG. TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol (Zurich, Switzerland). 2014; doi:10.1111/bpa.12190.
45. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif). 2001;25(4):402–8. doi:10.1006/meth.2001.1262.
47. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
48. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–31.
49. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006. doi:10.1101/gr.229102. Article published online before print in May 2002.
50. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463–7.
51. Kumaki Y, Oda M, Okano M. QUMA: quantification tool for methylation analysis. Nucleic Acids Res. 2008;36(Web Server issue):W170–5. doi:10.1093/nar/gkn294.